Skip to main content

GE Healthcare, PerkinElmer, Molecular Devices, Beckman Coulter

Premium

GE Healthcare Revenue Rises 7 Percent in Q3

GE Healthcare on Oct. 14 reported revenue of $3.6 billion for its third quarter ended Sept. 30, a 7-percent increase over revenue of $3.3 billion in the third quarter last year.

GE said total orders for GE Healthcare's Q3 were up 8 percent year over year. The services part of the unit reported 9-percent growth to $1.4 million, and the equipment part of the unit posted 7-percent growth to roughly $2.3 billion.

The healthcare unit of the conglomerate posted a quarterly profit of $589 million, a 17 percent increase year over year.

Overall, parent company GE posted revenue of $41.9 billion for the quarter, a 9-percent increase over revenue of $38.3 billion in the comparable quarter a year ago. The firm also reported net earnings of $4.7 billion, up 15 percent from $4.1 billion in the third quarter of 2004.

GE pointed out that all six of its business units — Healthcare, Infrastructure, Commercial Finance, Consumer Finance, Industrial, and NBC Universal — delivered double-digit earnings growth.


PerkinElmer, Molecular Devices, Beckman Coulter Schedule Q3 Earnings Release

PerkinElmer will release its third-quarter 2005 results on Tuesday, Oct. 25, following the close of market trading.

The company will hold a conference call and slide presentation via webcast to discuss the results that same evening, at 5:30 PM Eastern time. Gregory Summe, chairman and CEO, and Robert Friel, executive vice president and chief financial officer, will host the call.

Molecular Devices said it will release its third-quarter 2005 results on Thursday, Oct. 27, after the close of market trading.

Senior management will hold a conference call the following day, Friday, Oct. 28, at 11 AM Eastern time to discuss operating results and other business matters.

Beckman Coulter said it will release its third-quarter 2005 results on Wednesday, Nov. 2, 2005, before the start of regular market trading.

Beckman will host a conference call on that same morning, at 8:30 AM Eastern time to discuss the results. The call will be hosted by Scott Garrett, president and CEO, and James Glover, senior vice president and CFO.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.